Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. injectable therapy
Show results for
Products
Services
Training
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Injectable Therapy Articles & Analysis: Older

14 news found

Active Implants Receives FDA Breakthrough Device Designation for NUsurface Meniscus Implant

Active Implants Receives FDA Breakthrough Device Designation for NUsurface Meniscus Implant

“I’m pleased to hear the FDA will prioritize its review of this important new device and possibly make this therapy available for use by other knee surgeons for their American ...

ByActive Implants LLC


What to Expect for an Epidural Injection

What to Expect for an Epidural Injection

These injections can be repeated up to three times a year and should be performed in tandem with the physical therapy process. ...

ByMilestone Scientific, Inc.


Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million

Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million

Clearside intends to use the proceeds from the agreement to support ongoing clinical development of its pipeline, including CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector®. ...

ByClearside Biomedical


CD Formulation Launches Tailored Solutions for Increased Bioavailability Excipients for Drug Development

CD Formulation Launches Tailored Solutions for Increased Bioavailability Excipients for Drug Development

Classification of Increased Bioavailability Excipients Carbohydrate Carbohydrate-based parenteral excipients, such as trehalose, sucrose, mannitol, sorbitol and maltose, enable formulation scientists to stabilize large and small molecule injection therapies. Polymer Polymer excipients stabilize amorphous drugs in a solid state and then remain supersaturated in ...

ByCD Formulation


DiscGenics Announces Presentation of Positive Interim Clinical Data from Phase 1/2 Study of Cell Therapy for Degenerative Disc Disease

DiscGenics Announces Presentation of Positive Interim Clinical Data from Phase 1/2 Study of Cell Therapy for Degenerative Disc Disease

Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection; improvements were sustained at the one-year interim readout with additional data to follow at 18 and 24 months. Salt Lake City, UT ...

ByDiscGenics, Inc.


AOBiome’s B244 demonstrated positive results from its Phase 2b trial for both Pruritus (Itch) and Appearance of Atopic Dermatitis (Eczema)

AOBiome’s B244 demonstrated positive results from its Phase 2b trial for both Pruritus (Itch) and Appearance of Atopic Dermatitis (Eczema)

AOBiome Therapeutics, a clinical stage biotechnology company focused on transforming human health by developing topical biologic therapies for systemic inflammatory conditions, announced positive pivotal Phase 2b results from its trial evaluating B244 in both pruritus (itch) and appearance of atopic dermatitis (eczema). ...

ByAOBiome Therapeutic, LLC


Frontier Biotechnologies` First Long-acting Injectable (Aikening(R), in a Two Drug Regimen for HIV, Proves Safe and Efficacious for Patients

Frontier Biotechnologies` First Long-acting Injectable (Aikening(R), in a Two Drug Regimen for HIV, Proves Safe and Efficacious for Patients

The TALENT study (TALENT) findings, which were presented at the 11th International AIDS Society (IAS) Conference on HIV Science, showed that a two-drug regimen was as effective and safe as multi-drug therapies TALENT is the world's first phase III clinical trial of the new long-acting HIV-1 fusion inhibitor, Aikening® (generic name: Albuvirtide [ABT]) in an all-Asian ...

ByFrontier Biotechnologies Inc.


DiscGenics Completes Patient Enrollment in Japanese Clinical Study of Cell Therapy for Disc Degeneration as US Study Achieves One-Year Follow-up Milestone

DiscGenics Completes Patient Enrollment in Japanese Clinical Study of Cell Therapy for Disc Degeneration as US Study Achieves One-Year Follow-up Milestone

DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it has completed enrollment in its Japanese safety study of IDCT, an allogeneic, injectable Discogenic Cell therapy ...

ByDiscGenics, Inc.


ViGeneron signs global collaboration agreement for ophthalmic gene therapy development

ViGeneron signs global collaboration agreement for ophthalmic gene therapy development

Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional target The companies will use ViGeneron’s proprietary vgAAV technology to efficiently transduce target cells via intravitreal injections ViGeneron GmbH, a gene therapy company, today announced a global ...

ByViGeneron GmbH


DiscGenics Announces Completion of Enrollment in U.S. Phase 1/2 Clinical Trial of Discogenic Cell Therapy for Degenerative Disc Disease

DiscGenics Announces Completion of Enrollment in U.S. Phase 1/2 Clinical Trial of Discogenic Cell Therapy for Degenerative Disc Disease

DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it has completed enrollment in its Phase 1/2 first-in-human U.S. clinical study of IDCT, an allogeneic, injectable Discogenic Cell ...

ByDiscGenics, Inc.


Japanese Clinical Study of DiscGenics` Cell Therapy for Disc Degeneration Passes Initial Safety Review

Japanese Clinical Study of DiscGenics` Cell Therapy for Disc Degeneration Passes Initial Safety Review

Salt Lake City, UT and Tokyo, Japan – January 7, 2020 – DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that IDCT has passed the initial planned safety review of its double-blinded clinical ...

ByDiscGenics, Inc.


DiscGenics Announces Publication of Preclinical Data for Disc Degeneration Treatment in The Spine Journal

DiscGenics Announces Publication of Preclinical Data for Disc Degeneration Treatment in The Spine Journal

The manuscript, titled “In Vitro and In Vivo Evaluation of Discogenic Cells, An Investigational Cell Therapy for Disc Degeneration,” demonstrates that intradiscal injection of Discogenic Cells may be a viable treatment for human degenerative disc disease (DDD), citing that the cells produce extracellular matrix that may rebuild the depleting tissue ...

ByDiscGenics, Inc.


Final Patient Treated in Clinical Trials for Active Implants’ NUsurface Meniscus Implant

Final Patient Treated in Clinical Trials for Active Implants’ NUsurface Meniscus Implant

Current treatment for a damaged or torn meniscus includes pain management, physical therapy, injections, repair techniques or meniscectomy. It has been estimated that from 700,000 to over 1 million partial meniscectomies are performed annually in the U.S. in an attempt to alleviate pain; however, recent studies have shown that many people who get a meniscectomy ...

ByActive Implants LLC


TOCA (The Orthopedic Clinic Association) Performs First Meniscus Replacements in Arizona with NUsurface Meniscus Implant

TOCA (The Orthopedic Clinic Association) Performs First Meniscus Replacements in Arizona with NUsurface Meniscus Implant

Although he underwent three surgeries and injection therapy to treat the injury, he experienced constant pain that limited his daily activity. ...

ByActive Implants LLC

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT